meta|evidence oncology

Living systematic review and meta-analysis

locally advanced NSCLC - maintenance (M)
laNSCLC - M - all population 1
laNSCLC - M - EGFR mutant

immune chekpoint inhibitors
anti-PD-(L)1
durvalumab based treatment
durvalumab alone

versus all
vs non active control
vs placebo

study list
mapping
overview
meta-analysis
forest plot
NMA
excluded

Study		Exclusion reasons	Remarks	Reference(s)
Empty list - no studies excluded

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -